510(k) device
CRYOcheck Factor VIII Deficient Plasma with VWF
Precision Biologic, Inc. · Plasma, Coagulation Factor Deficient (GJT, Class II) · First FDA decision Sep 13, 2023, newest Sep 13, 2023Anemia, clotting and blood disorders
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
0
Naming "CRYOcheck"
MAUDE reports
0
Brand "CRYOcheck", since 2015
PubMed studies
10
Mentioning "CRYOcheck"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing CRYOcheck Factor VIII Deficient Plasma with VWF
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
K222831 · Decided Sep 13, 2023 · 359 days after receipt
Device type: Plasma, Coagulation Factor Deficient (GJT) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "CRYOcheck", any status and sponsor, newest update first.
No registered device study names "CRYOcheck".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "CRYOcheck", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code GJT
11 reports: 11 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "CRYOcheck"[tiab]. The summary above synthesizes these.
- [Evaluation of a semi-automated test for quantification of von Willebrand multimers].
Peronino C, Rivet N, Itzhar-Baikian N, et al. · Ann Biol Clin (Paris) · 2024Evaluation Study, English Abstract
- Variability among commercial batches of normal pooled plasma in lupus anticoagulant testing.
Cabo J, Morimont L, Baudar J, et al. · Int J Lab Hematol · 2023
- Fibrin deposition on bovine pericardium tissue used for bioprosthetic heart valve drives its calcification.
Poitier B, Rancic J, Richez U, et al. · Front Cardiovasc Med · 2023
- Study of in vitro thrombin generation after neutralization of heparin.
Hardy M, Douxfils J, Morimont L, et al. · Int J Lab Hematol · 2022
- A new-generation dilute Russell's viper venom time assay system for lupus anticoagulants: evaluation of detection utilising frozen reagents and controls.
Moore GW, Tugnait S, Savidge GF · Br J Biomed Sci · 2005Comparative Study, Evaluation Study
- Marked discrepancy between coagulometric protein C activity assays with the pro-thrombotic protein C Asn2Ile substitution.
Cooper PC, Siddiq S, Morse C, et al. · Int J Lab Hematol · 2011Case Reports
- Comparison of Russell viper venom-based and activated partial thromboplastin time-based screening assays for resistance to activated protein C.
Herskovits AZ, Lemire SJ, Longtine J, et al. · Am J Clin Pathol · 2008Comparative Study, Research Support, Non-U.S. Gov't
- Agreement between one stage and chromogenic assays in samples from patients receiving recombinant porcine FVIII (Obizur, Susoctocog-alfa).
Guy S, Bowyer AE, Shepherd MF, et al. · Int J Lab Hematol · 2024
- Functional Assessment of Platelet-Derived Phospholipid Activity in Pooled Normal Plasmas by Low-Phospholipid Thrombin Generation Assay and Its Impact on Lupus Anticoagulant Mixing Tests.
Kumano O, Matsuda M, Sakata M, et al. · Int J Lab Hematol · 2026
- Efficacy and Safety of Co-Ablation Combined With Aintilimab for Metastatic Melanoma to the Liver (CryoCheck-001): A Phase II Trial.
Shen L, Lin L, Chen S, et al. · MedComm (2020) · 2026
Other devices of this type
Also filed under product code GJT.
- HemosIL Factor XII Deficient PlasmaInstrumentation Laboratory CO · 510(k) 2018
- Nofact IXR2 Diagnostics, Inc. · 510(k) 2011
- Nofact VIIIR2 Diagnostics, Inc. · 510(k) 2011
- Diapharma Factor X KitDiapharma Group, Inc. · 510(k) 2004
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.